Scarica l'app Stockscreener
24.02
0.84%
0.20
Precedente Chiudi:
$23.82
Aprire:
$23.82
Volume 24 ore:
1.69M
Relative Volume:
1.71
Capitalizzazione di mercato:
$1.80B
Reddito:
$122.87M
Utile/perdita netta:
$-73.68M
Rapporto P/E:
-24.50
EPS:
-0.9803
Flusso di cassa netto:
$-39.27M
1 W Prestazione:
+29.70%
1M Prestazione:
+33.97%
6M Prestazione:
+101.17%
1 anno Prestazione:
+75.58%
Intervallo 1D:
$23.77
$25.00
Intervallo di 1 settimana:
$21.89
$26.19
Portata 52W:
$9.03
$26.19
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
24.02 | 1.80B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Press Release: Zymeworks Announced Positive Phase 3 HERIZON-GEA-01 Results - Oncodaily
B. Riley Securities Reiterates Zymeworks (ZYME) Buy Recommendation - Nasdaq
Zymeworks (NASDAQ:ZYME) Shares Up 5.5%What's Next? - MarketBeat
Zymeworks (NYSE:ZYME) Stock Price Up 5.4%Here's What Happened - MarketBeat
Zymeworks (ZYME) Gets a Rating Reiteration and Price Target Boos - GuruFocus
Zymeworks: Adjusting My Levels After Ziihera’s Phase III Data For GEA (NASDAQ:ZYME) - Seeking Alpha
How Zymeworks Inc. (ZA8) stock behaves in tightening cyclesShare Buyback & Stock Portfolio Risk Management - newser.com
Is Zymeworks Inc. stock a contrarian buySell Signal & Real-Time Buy Zone Alerts - newser.com
How to use Fibonacci retracement on Zymeworks Inc.2025 Performance Recap & Consistent Income Trade Ideas - newser.com
How Zymeworks Inc. stock compares to market leadersGold Moves & Precise Entry and Exit Recommendations - newser.com
How Zymeworks Inc. (ZA8) stock stacks up against competitorsEarnings Trend Report & Verified Technical Trade Signals - newser.com
Custom strategy builders for tracking Zymeworks Inc.Swing Trade & Safe Investment Capital Preservation Plans - newser.com
Is Zymeworks Inc. (ZA8) stock ideal for retirement investorsTrade Risk Assessment & Expert Approved Momentum Trade Ideas - newser.com
What technical patterns form on Zymeworks Inc. (ZA8) stock chartsBuy Signal & Low Drawdown Trading Strategies - newser.com
Zymeworks: A Lot Of Moving Parts (NASDAQ:ZYME) - Seeking Alpha
Is Zymeworks Inc. stock bottoming outWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Stifel Maintains Zymeworks (ZYME) Buy Recommendation - Nasdaq
Zymeworks (NYSE:ZYME) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Is Zymeworks Inc. (ZA8) stock nearing a technical breakoutWall Street Watch & Verified Technical Signals - newser.com
Stifel Raises Price Target for Zymeworks (ZYME) to $40 with Buy Rating | ZYME Stock News - GuruFocus
Zymeworks (NASDAQ:ZYME) Sets New 12-Month HighHere's What Happened - MarketBeat
Zymeworks stock price target raised to $40 from $30 at Stifel after trial success - Investing.com
Campbell & CO Investment Adviser LLC Purchases Shares of 14,985 Zymeworks Inc. $ZYME - MarketBeat
Why Zymeworks Inc. stock is in analyst buy zoneJuly 2025 Fed Impact & Daily Chart Pattern Signal Reports - newser.com
Can Zymeworks Inc. stock rebound after recent weaknessJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
EcoR1’s Platshon takes new role at Zymeworks amid strategy shift — and more - BioCentury
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer - wahanariau.com
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets - wahanariau.com
Why Zymeworks Inc. (ZA8) stock could outperform next yearQuarterly Trade Summary & High Win Rate Trade Tips - newser.com
Zymeworks (NYSE:ZYME) Shares Gap UpShould You Buy? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpTime to Buy? - MarketBeat
Zymeworks annouces a royalty-driven growth model (ZYME:NASDAQ) - Seeking Alpha
Zymeworks Inc. authorizes a Buyback Plan. - MarketScreener
Zymeworks Inc. announces an Equity Buyback for $125 million worth of its shares. - MarketScreener
HC Wainwright & Co. Maintains Zymeworks (ZYME) Buy Recommendation - Nasdaq
Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan - Stocktwits
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study - BioSpace
Zymeworks Announces Board and Executive Changes - MarketScreener
Zymeworks Appoints Scott Platshon as Acting CIO - TipRanks
Zymeworks Inc. Announces Board Resignation - TradingView
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up - simplywall.st
Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks stock hits four-year high on promising results from digestive cancer trial - The Globe and Mail
Published on: 2025-11-17 18:29:50 - newser.com
Jazz, Zymeworks unveil positive zanidatamab phase III data - BioWorld MedTech
Tools to monitor Zymeworks Inc. recovery probabilityForecast Cut & Smart Money Movement Alerts - newser.com
How moving averages guide Zymeworks Inc. trading2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - newser.com
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):